Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Porton Advanced Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Porton Advanced Teams with TongEYE on iPSC-RPEC Transplantation Therapy
Details : Porton will provide CDMO services to support iPSC-derived retinal pigment epithelium cell therapy program, including CMC development and IND application assistance.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Porton Advanced Solutions
Deal Size : Undisclosed
Deal Type : Collaboration